Header Logo

Connection

THOMAS MONATH to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications THOMAS MONATH has written about Antibodies, Viral.
THOMAS MONATH
Connection Strength
3.312
Antibodies, Viral
  1. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
    View in: PubMed
    Score: 0.239
  2. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol. 2009 Jul; 16(7):1052-9.
    View in: PubMed
    Score: 0.206
  3. Use of a surrogate chimeric virus to detect West Nile virus-neutralizing antibodies in avian and equine sera. Clin Vaccine Immunol. 2009 Jan; 16(1):134-5.
    View in: PubMed
    Score: 0.199
  4. rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
    View in: PubMed
    Score: 0.154
  5. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
    View in: PubMed
    Score: 0.144
  6. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis. 2002 Dec; 8(12):1392-7.
    View in: PubMed
    Score: 0.132
  7. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022 05 16; 132(10).
    View in: PubMed
    Score: 0.127
  8. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000 Jun; 74(12):5477-85.
    View in: PubMed
    Score: 0.111
  9. A short history of Lassa fever: the first 10-15 years after discovery. Curr Opin Virol. 2019 08; 37:77-83.
    View in: PubMed
    Score: 0.104
  10. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev. 1999 Jul; 12(3):383-93.
    View in: PubMed
    Score: 0.104
  11. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 07; 18(7):738-748.
    View in: PubMed
    Score: 0.095
  12. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996 Aug; 174(2):256-61.
    View in: PubMed
    Score: 0.085
  13. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother. 1994 Dec; 38(12):2785-91.
    View in: PubMed
    Score: 0.076
  14. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
    View in: PubMed
    Score: 0.071
  15. Yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg. 2011 Oct; 85(4):748-9.
    View in: PubMed
    Score: 0.061
  16. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
    View in: PubMed
    Score: 0.059
  17. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990 May; 161(5):878-82.
    View in: PubMed
    Score: 0.055
  18. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
    View in: PubMed
    Score: 0.055
  19. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009 Mar 04; 27(10):1637-44.
    View in: PubMed
    Score: 0.050
  20. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine. 2008 Jan 24; 26(4):581-8.
    View in: PubMed
    Score: 0.046
  21. Multisite monoclonal immunoassay for dengue viruses: detection of viraemic human sera and interference by heterologous antibody. J Gen Virol. 1986 Apr; 67 ( Pt 4):639-50.
    View in: PubMed
    Score: 0.041
  22. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
    View in: PubMed
    Score: 0.041
  23. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14.
    View in: PubMed
    Score: 0.040
  24. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine. 2005 May 09; 23(25):3301-9.
    View in: PubMed
    Score: 0.039
  25. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
    View in: PubMed
    Score: 0.038
  26. Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis. J Clin Microbiol. 1984 Oct; 20(4):784-90.
    View in: PubMed
    Score: 0.037
  27. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.037
  28. Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am J Trop Med Hyg. 1984 Jul; 33(4):695-8.
    View in: PubMed
    Score: 0.037
  29. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
    View in: PubMed
    Score: 0.035
  30. Serodiagnosis of western equine encephalitis virus infections: relationships of antibody titer and test to observed onset of clinical illness. J Am Vet Med Assoc. 1983 Aug 15; 183(4):438-40.
    View in: PubMed
    Score: 0.035
  31. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
    View in: PubMed
    Score: 0.033
  32. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg Microbes Infect. 2022 Dec; 11(1):2724-2734.
    View in: PubMed
    Score: 0.033
  33. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. J Infect Dis. 2022 10 17; 226(8):1401-1406.
    View in: PubMed
    Score: 0.033
  34. Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
    View in: PubMed
    Score: 0.032
  35. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002 Jun 20; 298(1):146-59.
    View in: PubMed
    Score: 0.032
  36. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
    View in: PubMed
    Score: 0.032
  37. A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. J Infect Dis. 2022 04 19; 225(8):1399-1410.
    View in: PubMed
    Score: 0.032
  38. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.031
  39. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
    View in: PubMed
    Score: 0.031
  40. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol. 2002; 267:105-38.
    View in: PubMed
    Score: 0.031
  41. Transcriptomic signatures induced by the Ebola virus vaccine rVSV?G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. Lancet Microbe. 2022 02; 3(2):e113-e123.
    View in: PubMed
    Score: 0.031
  42. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Eng. 1999 Apr; 12(4):357-62.
    View in: PubMed
    Score: 0.026
  43. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
    View in: PubMed
    Score: 0.023
  44. Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
    View in: PubMed
    Score: 0.023
  45. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector. Clin Vaccine Immunol. 2017 Jan; 24(1).
    View in: PubMed
    Score: 0.022
  46. Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. Vaccine. 2017 01 03; 35(1):1-9.
    View in: PubMed
    Score: 0.022
  47. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016 Apr 12; 34(17):1993-9.
    View in: PubMed
    Score: 0.021
  48. Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
    View in: PubMed
    Score: 0.019
  49. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
    View in: PubMed
    Score: 0.019
  50. Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hosts. Trans R Soc Trop Med Hyg. 1974; 68(1):30-8.
    View in: PubMed
    Score: 0.018
  51. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
    View in: PubMed
    Score: 0.017
  52. Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine. 2012 Jan 05; 30(2):254-64.
    View in: PubMed
    Score: 0.015
  53. Human infections with Tensaw virus in south Florida: evidence that Tensaw virus subtypes stimulate the production of antibodies reactive with closely related Bunyamwera serogroup viruses. Am J Trop Med Hyg. 1988 Jul; 39(1):117-22.
    View in: PubMed
    Score: 0.012
  54. Epizootic vesicular stomatitis in Colorado, 1982: some observations on the possible role of wildlife populations in an enzootic maintenance cycle. J Wildl Dis. 1987 Apr; 23(2):192-8.
    View in: PubMed
    Score: 0.011
  55. Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984. Bull World Health Organ. 1987; 65(6):855-60.
    View in: PubMed
    Score: 0.011
  56. Geographic classification of dengue-2 virus strains by antigen signature analysis. Virology. 1986 Oct 30; 154(2):313-24.
    View in: PubMed
    Score: 0.011
  57. Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. J Clin Microbiol. 1986 Jan; 23(1):129-34.
    View in: PubMed
    Score: 0.010
  58. Arbovirus investigations in Argentina, 1977-1980. IV. Serologic surveys and sentinel equine program. Am J Trop Med Hyg. 1985 Sep; 34(5):966-75.
    View in: PubMed
    Score: 0.010
  59. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004 Sep 09; 22(27-28):3722-6.
    View in: PubMed
    Score: 0.009
  60. Detection of yellow fever virus in serum by enzyme immunoassay. Am J Trop Med Hyg. 1984 Jan; 33(1):151-7.
    View in: PubMed
    Score: 0.009
  61. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis. 2003 Aug 01; 188(3):440-8.
    View in: PubMed
    Score: 0.009
  62. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. J Gen Virol. 1983 Mar; 64 Pt 3:627-37.
    View in: PubMed
    Score: 0.008
  63. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
    View in: PubMed
    Score: 0.008
  64. Diagnosis of eastern equine encephalomyelitis by immunofluorescent staining of brain tissue. Am J Vet Res. 1981 Aug; 42(8):1418-21.
    View in: PubMed
    Score: 0.008
  65. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59(6):895-900.
    View in: PubMed
    Score: 0.007
  66. Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans R Soc Trop Med Hyg. 1981; 75(2):282-6.
    View in: PubMed
    Score: 0.007
  67. Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980 Sep; 29(5):912-28.
    View in: PubMed
    Score: 0.007
  68. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. Trans R Soc Trop Med Hyg. 1977; 71(1):60-5.
    View in: PubMed
    Score: 0.005
  69. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg. 1974 Nov; 23(6):1140-9.
    View in: PubMed
    Score: 0.005
  70. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993 May-Jun; 87(3):337-9.
    View in: PubMed
    Score: 0.004
  71. Importance of nonhuman primates in yellow fever epidemiology in Nigeria. Trop Geogr Med. 1973 Mar; 25(1):28-38.
    View in: PubMed
    Score: 0.004
  72. The 1970 yellow fever epidemic in Okwoga District Benue Plateau State, Nigeria. 2. Immunity survey to determine geographic limits and origins of the epidemic. Bull World Health Organ. 1973; 49(2):123-8.
    View in: PubMed
    Score: 0.004
  73. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity. Bull World Health Organ. 1973; 49(3):235-44.
    View in: PubMed
    Score: 0.004
  74. Studies on Tataguine infection in Nigeria. Trop Geogr Med. 1972 Sep; 24(3):298-302.
    View in: PubMed
    Score: 0.004
  75. Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol. 1988 Aug; 69 ( Pt 8):1921-9.
    View in: PubMed
    Score: 0.003
  76. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am J Trop Med Hyg. 1987 Jan; 36(1):177-82.
    View in: PubMed
    Score: 0.003
  77. Epizootic vesicular stomatitis in Colorado, 1982: epidemiologic studies along the northern Colorado front range. Am J Trop Med Hyg. 1987 Jan; 36(1):183-8.
    View in: PubMed
    Score: 0.003
  78. Investigations of the vertebrate hosts of eastern equine encephalitis during an epizootic in Michigan, 1980. Am J Trop Med Hyg. 1985 Nov; 34(6):1190-202.
    View in: PubMed
    Score: 0.003
  79. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984; 62(4):585-90.
    View in: PubMed
    Score: 0.002
  80. Reported encephalitis associated with California serogroup virus infections in the United States, 1963-1981. Prog Clin Biol Res. 1983; 123:31-41.
    View in: PubMed
    Score: 0.002
  81. Arbovirus infections among laboratory personnel in Ibadan, Nigeria. Am J Trop Med Hyg. 1981 Jul; 30(4):855-61.
    View in: PubMed
    Score: 0.002
  82. Bwamba virus infection: a sero-survey of veterbrates in five ecological zones in Nigeria. Trans R Soc Trop Med Hyg. 1974; 68(6):461-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.